MCID: HMG002
MIFTS: 49

Hemoglobinuria

Categories: Blood diseases, Immune diseases, Nephrological diseases

Aliases & Classifications for Hemoglobinuria

Summaries for Hemoglobinuria

MalaCards based summary : Hemoglobinuria is related to paroxysmal nocturnal hemoglobinuria 1 and aplastic anemia, and has symptoms including chyluria and other and unspecified genitourinary symptoms. An important gene associated with Hemoglobinuria is PIGA (Phosphatidylinositol Glycan Anchor Biosynthesis Class A), and among its related pathways/superpathways are Innate Immune System and Cell surface interactions at the vascular wall. The drugs tannic acid and Warfarin have been mentioned in the context of this disorder. Affiliated tissues include bone, bone marrow and kidney, and related phenotypes are hematopoietic system and homeostasis/metabolism

Wikipedia : 74 Hemoglobinuria is a condition in which the oxygen transport protein hemoglobin is found in abnormally... more...

Related Diseases for Hemoglobinuria

Diseases related to Hemoglobinuria via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 411)
# Related Disease Score Top Affiliating Genes
1 paroxysmal nocturnal hemoglobinuria 1 35.0 PIGT PIGA
2 aplastic anemia 32.5 THBD SERPINC1 PIGA CSF3 CD59 CD55
3 blackwater fever 32.4 MB HP G6PD
4 thrombophilia due to thrombin defect 31.4 THBD SERPINC1 F2
5 budd-chiari syndrome 31.2 SERPINC1 F2 CD59
6 acute kidney failure 31.1 MB HP F2
7 myelodysplastic syndrome 31.0 PIGA CSF3 CR1 CD59 CD55
8 thrombosis 30.9 THBD SERPINC1 F2 CD55
9 retinitis pigmentosa and erythrocytic microcytosis 30.9 PIGA CSF3
10 paroxysmal nocturnal hemoglobinuria 30.8 THBD SERPINC1 PLAUR PIGT PIGH PIGA
11 multiple congenital anomalies-hypotonia-seizures syndrome 2 30.6 PIGT PIGA CD59 CD55
12 purpura 30.6 THBD SERPINC1 F2 C3
13 anemia, autoimmune hemolytic 30.6 HP G6PD CD59 CD55 C3
14 severe pre-eclampsia 30.4 SERPINC1 C5 C3
15 hypersplenism 30.4 SERPINC1 F2 CSF3
16 deficiency anemia 30.4 MB HP G6PD CSF3 CR1 CD59
17 sagittal sinus thrombosis 30.2 SERPINC1 F2
18 branch retinal artery occlusion 30.2 SERPINC1 F2
19 splenic infarction 30.2 SERPINC1 HP F2
20 aseptic meningitis 30.1 CSF3 CFI CD58
21 leukemia, chronic lymphocytic 30.1 FCGR3B CSF3 CR1 CD59 CD58 CD55
22 bilirubin metabolic disorder 30.1 HP G6PD F2
23 hemolytic anemia 30.1 THBD PIGA HP G6PD CR1 CFI
24 splenic sequestration 30.1 HP F2
25 varicose veins 30.0 THBD SERPINC1 F2
26 disseminated intravascular coagulation 30.0 THBD SERPINC1 MB F2
27 enterocolitis 30.0 CFI C3
28 intracranial embolism 30.0 SERPINC1 F2
29 pulmonary embolism 29.9 THBD SERPINC1 MB F2
30 thrombocytopenia 29.9 THBD SERPINC1 HP F2 CSF3 CFI
31 antiphospholipid syndrome 29.9 THBD SERPINC1 F2 C3
32 genetic atypical hemolytic-uremic syndrome 29.9 THBD CFI C3
33 essential thrombocythemia 29.9 THBD SERPINC1 F2 CSF3
34 anuria 29.9 MB HP F2
35 hepatic coma 29.9 SERPINC1 F2
36 thrombocytosis 29.9 SERPINC1 F2 CSF3
37 sickle cell anemia 29.8 G6PD F2 CSF3
38 central retinal artery occlusion 29.8 SERPINC1 F2
39 homocysteinemia 29.8 THBD SERPINC1 F2
40 glomerulonephritis 29.7 CR1 CFI CD55 C3
41 peripheral vascular disease 29.7 THBD SERPINC1 F2
42 pneumonia 29.7 MB F2 CSF3 CR1
43 central retinal vein occlusion 29.6 SERPINC1 G6PD F2
44 thrombotic thrombocytopenic purpura 29.6 THBD SERPINC1 HP CFI C3
45 hemolytic-uremic syndrome 29.5 THBD HP F2 CFI CD55 C5
46 stroke, ischemic 29.2 THBD SERPINC1 MB F2
47 hemolytic uremic syndrome, atypical 1 29.1 THBD PIGA HP CR1 CFI CD59
48 myocardial infarction 28.9 THBD SERPINC1 MB HP F2 CSF3
49 systemic lupus erythematosus 28.7 THBD FCGR3B F2 CSF3 CR1 CFI
50 malaria 27.4 THBD SERPINC1 PLAUR MB HP G6PD

Graphical network of the top 20 diseases related to Hemoglobinuria:



Diseases related to Hemoglobinuria

Symptoms & Phenotypes for Hemoglobinuria

UMLS symptoms related to Hemoglobinuria:


chyluria, other and unspecified genitourinary symptoms

MGI Mouse Phenotypes related to Hemoglobinuria:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10 C3 CD55 CD59 CFI CSF3 F2
2 homeostasis/metabolism MP:0005376 9.8 C3 C5 CD59 CFI F2 FCGR3B
3 renal/urinary system MP:0005367 9.23 C3 CD59 CFI CSF3 HP PLAUR

Drugs & Therapeutics for Hemoglobinuria

Drugs for Hemoglobinuria (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 105)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
tannic acid Approved Phase 4 1401-55-4
2
Warfarin Approved Phase 4 81-81-2 6691 54678486
3
Sirolimus Approved, Investigational Phase 4 53123-88-9 5284616 6436030 46835353
4
Benzocaine Approved, Investigational Phase 4 1994-09-7, 94-09-7 2337
5
Everolimus Approved Phase 4 159351-69-6 6442177 70789204
6 Pharmaceutical Solutions Phase 4
7 Antibodies, Monoclonal Phase 4
8 Complement C5 Phase 4
9 Thymoglobulin Phase 4
10 Immunoglobulins, Intravenous Phase 4
11 Rho(D) Immune Globulin Phase 4
12 gamma-Globulins Phase 4
13 Complement C3 Phase 4
14 Complement C3d Phase 4
15 Anticoagulants Phase 4
16 Antibiotics, Antitubercular Phase 4
17 Anti-Bacterial Agents Phase 4
18
Iodine Approved, Investigational Phase 3 7553-56-2 807
19
Thiotepa Approved, Investigational Phase 3 52-24-4 5453
20
Protein C Approved Phase 3
21
Ravulizumab Approved, Investigational Phase 3 1803171-55-2
22 Antilymphocyte Serum Phase 3
23 Muromonab-CD3 Phase 3
24 Complement Inactivating Agents Phase 3
25
Basiliximab Approved, Investigational Phase 2 179045-86-4, 152923-56-3
26
Sargramostim Approved, Investigational Phase 2 123774-72-1, 83869-56-1
27
Mechlorethamine Approved, Investigational Phase 2 51-75-2 4033
28
Mesna Approved, Investigational Phase 2 3375-50-6 598
29
Lenograstim Approved, Investigational Phase 2 135968-09-1
30
Busulfan Approved, Investigational Phase 2 55-98-1 2478
31
Melphalan Approved Phase 2 148-82-3 4053 460612
32
Etoposide Approved Phase 2 33419-42-0 36462
33
Vidarabine Approved, Investigational Phase 2 24356-66-9 32326 21704
34
Methotrexate Approved Phase 2 1959-05-2, 59-05-2 126941
35
leucovorin Approved Phase 2 58-05-9 6006 143
36
Mycophenolic acid Approved Phase 2 24280-93-1 446541
37
Miconazole Approved, Investigational, Vet_approved Phase 1, Phase 2 22916-47-8 4189
38
alemtuzumab Approved, Investigational Phase 1, Phase 2 216503-57-0
39
Fludarabine Approved Phase 1, Phase 2 21679-14-1, 75607-67-9 30751
40
Tacrolimus Approved, Investigational Phase 1, Phase 2 104987-11-3 445643 439492 6473866
41
Phenylalanine Approved, Investigational, Nutraceutical Phase 2 63-91-2 6140
42
Folic acid Approved, Nutraceutical, Vet_approved Phase 2 59-30-3 6037
43
Emodepside Investigational, Vet_approved Phase 2 155030-63-0
44 Hormone Antagonists Phase 2
45 glucocorticoids Phase 2
46 Hormones Phase 2
47 Adjuvants, Immunologic Phase 2
48 Protective Agents Phase 2
49 Alkylating Agents Phase 2
50 Etoposide phosphate Phase 2

Interventional clinical trials:

(show top 50) (show all 116)
# Name Status NCT ID Phase Drugs
1 An Open-Label Multi-Center Study of Eculizumab in Children and Adolescents With a Diagnosis of Paroxysmal Nocturnal Hemoglobinuria Completed NCT00867932 Phase 4 Eculizumab
2 Treatment With Thrombopoietin Mimetic Plus Immunosuppressive Therapy in Egyptian Patients With Aplastic Anaemia Recruiting NCT03896971 Phase 4 Combination of thrombopoietin mimetic and cyclosporin A
3 The De-novo Use of Eculizumab Alongside Conventional Therapy in Presensitized Patients Receiving Cardiac Transplantation: An Open-Label, Investigator-Initiated Pilot Trial: [The DUET Cardiac Trial] Active, not recruiting NCT02013037 Phase 4 Eculizumab
4 Sirolimus Combined With Low-dose Warfarin for the Treatment of Refractory Classic Paroxysmal Nocturnal Hemoglobinuria ,a Prospective Study Not yet recruiting NCT03866681 Phase 4 sirolimus
5 Diet Challenge in G6PD Deficient Egyptian Children: A One- Year Prospective Single Center Study With Genotype - Phenotype Correlation Unknown status NCT02498340 Phase 2, Phase 3
6 Open Label Extension Study of Eculizumab in Patients With Transfusion Dependent PNH Completed NCT00122317 Phase 3 eculizumab
7 Randomized, Double-Blind, and Placebo-Controlled Study Using Eculizumab in Transfusion Dependent PNH Patients Completed NCT00122330 Phase 3 eculizumab
8 Safety in Hemolytic PNH Patients Treated With Eculizumab: a Multi-Center Open-Label Research Design Study Completed NCT00122304 Phase 3 eculizumab
9 A Hemoglobin Stabilization and Transfusion Reduction Efficacy and Safety Clinical Investigation, Randomized, Multi-Center, Double-Blind, Placebo-Controlled, Using Eculizumab in Paroxysmal Nocturnal Hemoglobinuria Patients Completed NCT00098280 Phase 3 Eculizumab
10 TRIUMPH: A Hemoglobin Stabilization and Transfusion Reduction Efficacy and Safety Clinical Investigation, Randomized, Multi-Center, Double-Blind, Placebo-Controlled, Using Eculizumab in Paroxysmal Nocturnal Hemoglobinuria Patients Completed NCT00112983 Phase 3
11 SHEPHERD: Safety in Hemolytic PNH Patients Treated With Eculizumab: A Multi-Center Open-Label Research Design Completed NCT00130000 Phase 3 Eculizumab
12 Hematopoietic Stem Cell Transplantation Using Matched Unrelated Donor Peripheral Blood or Bone Marrow for Patients With Hematologic Malignancies Completed NCT00152139 Phase 3 Chemotherapy and antibodies
13 Haploidentical Stem Cell Transplantation Utilizing Purified CD34+ Hematopoietic Cells for Patients With Hematologic Malignancies Completed NCT00186823 Phase 3 TBI, systemic chemotherapy and antibodies as follows:
14 Randomized Comparison of Cyclophosphamide Versus Cyclophosphamide Plus Fludarabine In Addition To Anti-Thymocyte Globulin for the Conditioning Therapy in Allogeneic Hematopoietic Cell Transplantation for Bone Marrow Failure Syndrome Completed NCT00774527 Phase 3 Cyclophosphamide-fludarabine-anti thymocyte globulin
15 A Phase 3, Randomized, Multicenter, Open-Label, Controlled Study to Evaluate the Efficacy and Safety of APL-2 in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Recruiting NCT04085601 Phase 3 APL-2
16 A Randomized, Double-Blind, Active-Controlled Phase 3 Study Evaluating the Efficacy and Safety of ABP 959 Compared With Eculizumab in Adult Subjects With Paroxysmal Nocturnal Hemoglobinuria (PNH) Recruiting NCT03818607 Phase 3 ABP 959;Eculizumab
17 A Phase 3, Open-Label Study of ALXN1210 in Children and Adolescents With Paroxysmal Nocturnal Hemoglobinuria (PNH) Recruiting NCT03406507 Phase 3
18 CONSERVE: rVA576 (Coversin) Long Term Safety and Efficacy Surveillance Study Recruiting NCT03829449 Phase 3 rVA576 (Coversin)
19 Randomized, Open-Label, International, Multi-center, Comparative Study of Efficacy and Safety of BCD-148 (JSC BIOCAD, Russia) and Soliris® in Patients With Paroxysmal Nocturnal Hemoglobinuria Recruiting NCT04060264 Phase 3
20 Investigational Product ; Coversin. Phase III Safety and Efficacy in Three-Part, Two-Arm, Randomised Open Label Evaluation in Patients With Paroxysmal Nocturnal Haemoglobinuria (PNH) Recruiting NCT03588026 Phase 3 rVA576
21 A Phase III Randomised, Double-blind, Multicentre Study to Compare the Efficacy, Safety, Pharmacokinetics, and Immunogenicity Between SB12 (Proposed Eculizumab Biosimilar) and Soliris® in Subjects With Paroxysmal Nocturnal Haemoglobinuria Recruiting NCT04058158 Phase 3 SB12 (proposed eculizumab biosimilar);Soliris (eculizumab)
22 A Phase III, Randomized, Multi-Center, Open-Label, Active-Comparator Controlled Study to Evaluate the Efficacy and Safety of APL-2 in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Active, not recruiting NCT03500549 Phase 3 APL-2;Soliris
23 A Phase 3, Randomized, Open-Label, Active-Controlled Study of ALXN1210 Versus Eculizumab in Complement Inhibitor-Naïve Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Active, not recruiting NCT02946463 Phase 3
24 A Phase 3, Randomized, Open-Label, Active-Controlled Study of ALXN1210 Versus Eculizumab in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Eculizumab Active, not recruiting NCT03056040 Phase 3
25 An Open Label, Non-Randomized, Multi-Center Extension Study to Evaluate the Long-Term Safety and Efficacy of APL-2 in the Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH) Enrolling by invitation NCT03531255 Phase 3 APL-2
26 An Open-label Extension Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of REGN3918 in Patients With Paroxysmal Nocturnal Hemoglobinuria Not yet recruiting NCT04162470 Phase 3 REGN3918
27 Phase II Study of the Levamisole Combined With Cyclosporine A in Patients With Classic Paroxysmal Nocturnal Hemoglobinuria Unknown status NCT01642979 Phase 2 Levamisole+cyclosporin A+Glucocorticoids;cyclosporin A+Glucocorticoids;Glucocorticoids
28 Phase II Study of the Levamisole Combined With Cyclosporine A in Patients With Subclinical Paroxysmal Nocturnal Hemoglobinuria and PNH in the Setting of Another Bone Marrow Failure Syndromes(PNH-2013) Unknown status NCT01760096 Phase 2 Levamisole+cyclosporin A+Glucocorticoids;cyclosporin A+Glucocorticoids;Glucocorticoids
29 An Open Label Study of the Effects of Eculizumab in CD59 Deficiency Unknown status NCT01579838 Phase 1, Phase 2 Eculizumab
30 Alemtuzumab and Low-Dose Cyclosporine-A as Alternative Immunosuppressive Treatment for Severe Aplastic Anemia (SAA) and Single-Lineage Aplastic Patients Unknown status NCT00895739 Phase 2 cyclosporine
31 A Phase 2 Multicenter, Open-Label, Uncontrolled Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of RA101495 in Subjects With Paroxysmal Nocturnal Hemoglobinuria Who Have an Inadequate Response to Eculizumab Completed NCT03030183 Phase 2 Zilucoplan (RA101495)
32 A Phase 2 Open-Label Proof of Concept Study to Assess the Efficacy, Safety, and Pharmacokinetics of ACH-0144471 in Untreated Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Completed NCT03053102 Phase 2 ACH-0144471
33 Phase II Clinical Study of Eculizumab (h5G1.1-mAb) in Hemolytic Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients: Extension Study to C07-001 Protocol Completed NCT01194804 Phase 2 Eculizumab
34 Phase II Clinical Study of Eculizumab (h5G1.1-mAb) in Hemolytic Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients Completed NCT01192399 Phase 2
35 A Phase 1/2 Single-ascending and Multiple-ascending Dose, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Study of Subcutaneously Administered ALN-CC5 in Healthy Adult Volunteers and Patients With Paroxysmal Nocturnal Hemoglobinuria Completed NCT02352493 Phase 1, Phase 2 ALN-CC5;Sterile Normal Saline (0.9% NaCl)
36 Phase 2 Multicenter, Open-Label, Uncontrolled Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of RA101495 in Subjects With Paroxysmal Nocturnal Hemoglobinuria Completed NCT03078582 Phase 2 RA101495
37 High Dose Cyclophosphamide for the Treatment of Severe Aplastic Anemia and Paroxysmal Nocturnal Hemoglobinuria Completed NCT00004464 Phase 2 cyclophosphamide;filgrastim
38 A Phase II Study of Reduced-Intensity Allogeneic Peripheral Blood Stem Cell Transplantation (PBSCT) for Treatment of Hematologic Malignancies and Hematopoietic Failure States Completed NCT00997386 Phase 2 busulfan, and melphalan, and alemtuzumab
39 Coversin in Paroxysmal Nocturnal Haemoglobinuria (PNH) in Patients With Resistance to Eculizumab Due to Complement C5 Polymorphisms Completed NCT02591862 Phase 2 Coversin
40 HLA-HAPLOIDENTICAL FAMILIAL DONOR HEMATOPOIETIC CELL TRANSPLANTATION AFTER REDUCED INTENSITY CONDITIONING OF BUSULFAN, FLUDARABINE, AND ANTI-THYMOCYTE GLOBULIN FOR PATIENTS WITH BONE MARROW FAILURE SYNDROME - A PHASE 2 STUDY Completed NCT00731328 Phase 2
41 Basiliximab #2: In-Vivo Activated T-Cell Depletion to Prevent GVHD After Nonmyeloablative Allotransplantation for the Treatment of Blood Cancer Completed NCT00975975 Phase 2 Basiliximab
42 Phase II Trial of Allogeneic T-Cell Depleted Hematopoietic Stem Cell Transplants From HLA Compatible, Related and Unrelated Donors After a Myeloablative Preparative Regimen With Hyperfractionated TBI, Thiotepa and Fludarabine For Treatment of Adult Patients (>18 Years) With Lymphohematopoietic Disorders Completed NCT00587054 Phase 2 cytoreductive regimen followed by a CD34+E- selected allogeneic stem cell transplant
43 Allogeneic Mixed Chimerism Stem Cell Transplantation Utilizing In Vivo and In Vitro Campath for Hemoglobinopathies and Bone Marrow Failure Syndromes Completed NCT00004143 Phase 2 Campath, Chemo and/or TBI Allo SCT
44 A Phase II Trial of Reduced Intensity Allogeneic Stem Cell Transplantation With Fludarabine, Melphalan and Low Dose Total Body Irradiation Completed NCT01529827 Phase 2 fludarabine phosphate;melphalan;tacrolimus;mycophenolate mofetil;methotrexate
45 A Randomized Trial of Immunosuppression in Aplastic Anemia Patients With Refractory Pancytopenia or Suboptimal Hematologic Response After h-ATG/CsA Treatment Completed NCT00065260 Phase 2 Campath-1H;r-ATG;CsA
46 Haploidentical Stem Cell Transplantation Utilizing T-Cell Depletion as Therapy for Patients With Refractory Hematological Malignancies Completed NCT00145613 Phase 2 Systemic chemotherapy and antibodies
47 A Phase II Study of Peripheral Blood Stem Cell Transplantation (PBSCT)From Haploidentical Related Donors for Treatment of Hematologic Malignancies and Hematopoietic Failure States Completed NCT00618969 Phase 2
48 An Open Label Study of the Effects of Eculizumab in Neuromyelitis Optica Completed NCT00904826 Phase 1, Phase 2 Eculizumab
49 A Reduced Intensity Conditioning Regimen With CD3-Depleted Hematopoietic Stem Cells to Improve Survival for Patients With Hematologic Malignancies Undergoing Haploidentical Stem Cell Transplantation Completed NCT00566696 Phase 2 Fludarabine;Thioplex®;L-phenylalanine mustard;Mycophenolate mofetil;Rituxan™;Alemtuzumab;Cyclophosphamide;Anti-thymocyte globulin (Rabbit);G-CSF;Muromonab
50 Haploidentical Hematopoietic Stem Cell Transplantation Utilizing Partial T-Cell Depletion as Immunotherapy for Hematologic Malignancies Completed NCT00143559 Phase 2 Systematic chemotherapy and antibodies

Search NIH Clinical Center for Hemoglobinuria

Cochrane evidence based reviews: hemoglobinuria

Genetic Tests for Hemoglobinuria

Genetic tests related to Hemoglobinuria:

# Genetic test Affiliating Genes
1 Hemoglobinuria 29

Anatomical Context for Hemoglobinuria

MalaCards organs/tissues related to Hemoglobinuria:

40
Bone, Bone Marrow, Kidney, T Cells, Testes, Monocytes, Neutrophil

Publications for Hemoglobinuria

Articles related to Hemoglobinuria:

(show top 50) (show all 3358)
# Title Authors PMID Year
1
The prevalence of G6PD deficiency in blood transfusion recipients. 54 61
17364999 2007
2
[Post-hemolytic renal failure in children with glucose-6-phosphate dehydrogenase deficiency at the University Hospital Center in Lome]. 54 61
12910652 2003
3
Ethanol sclerotherapy of venous malformations: evaluation of systemic ethanol contamination. 54 61
11340138 2001
4
Acute myelogenous leukemia with PIG-A gene mutation evolved from aplastic anemia-paroxysmal nocturnal hemoglobinuria syndrome. 54 61
11372733 2001
5
Paroxysmal nocturnal hemoglobinuria: An acquired genetic disease. 54 61
10539884 1999
6
Paroxysmal nocturnal hemoglobinuria: molecular pathogenesis and molecular therapeutic approaches. 54 61
9844822 1998
7
Blackwater fever in southern Vietnam: a prospective descriptive study of 50 cases. 54 61
8953071 1996
8
Serum transcobalamin II level in glucose-6-phosphate dehydrogenase deficient subjects with typhoid fever. 54 61
8708525 1996
9
Persistently elevated serum transcobalamin II in a patient with cerebral malaria and typhus infections. 54 61
7622977 1995
10
Repeated large-dose haptoglobin therapy in an extensively burned patient: case report. 54 61
8163802 1994
11
Hemolytic effect of the Amplatz thrombectomy device. 54 61
8136596 1994
12
[Intensive care of a postpartum patient complicated with HELLP syndrome]. 54 61
8320814 1993
13
Regulation of renal function in thermal injury. 54 61
2147724 1990
14
[Administration of haptoglobin in ABO incompatible bone marrow transplantation]. 54 61
2255063 1990
15
[The Outcome of Severe Aplastic Anemia Children Treated with Reduced Dose of Cyclophosphamide Combined Cyclosporine A]. 61
32027281 2020
16
Ravulizumab for the treatment of paroxysmal nocturnal hemoglobinuria. 61
32011183 2020
17
Analysis of platelets by flow cytometry in patients with Paroxysmal Nocturnal Hemoglobinuria (PNH). 61
31710879 2020
18
Case Report: A Case of Acute Intravascular Hemolysis in Dengue Fever. 61
31912775 2020
19
Soluble NKG2D Ligands Are Potential Biomarkers and Sentinels of Immune-Mediated Bone Marrow Injury in Bone Marrow Failure Syndromes. 61
31216534 2020
20
Evaluation of laboratory investigative methods of diagnosing clonal hematological disorders in a resource-poor setting. 61
31929204 2020
21
Analysis of clinical characteristics of 92 patients with paroxysmal nocturnal hemoglobinuria: A single institution experience in China. 61
31502726 2020
22
The complement C5 inhibitor crovalimab in paroxysmal nocturnal hemoglobinuria. 61
31978221 2020
23
A Rare Case of Paroxysmal Nocturnal Hemoglobinuria with Renal Manifestation. 61
31979936 2020
24
Second-Generation C5 Inhibitors for Paroxysmal Nocturnal Hemoglobinuria. 61
31916226 2020
25
Leukemia evolving from paroxysmal nocturnal hemoglobinuria. 61
31431736 2020
26
Characterization of breakthrough hemolysis events observed in the phase 3 randomized studies of ravulizumab versus eculizumab in adults with paroxysmal nocturnal hemoglobinuria. 61
31949012 2020
27
Paroxysmal cold hemoglobinuria: a unique constellation of peripheral smear findings. 61
31999817 2020
28
Case Report: A Case of Primaquine-Induced Hemoglobinuria in Glucose-6-Phosphate Dehydrogenase Deficient Malaria Patient in Southeastern Bangladesh. 61
31701865 2020
29
Prevalence of Paroxysmal Nocturnal Hemoglobinuria Clones in Myeloproliferative Neoplasm Patients: A Cross-Sectional Study. 61
31601527 2019
30
Idiopathic aplastic anemia vs hypocellular myelodysplastic syndrome. 61
31808900 2019
31
Clonal dynamics of aplastic anemia/paroxysmal nocturnal hemoglobinuria. 61
31885297 2019
32
Paroxysmal Nocturnal Hemoglobinuria: Case Report of a Rare Cause of Thrombosis in the Pediatric Age. 61
31842179 2019
33
Sclerotherapy with Adjunctive Stasis of Efflux (STASE) in Venous Malformations: Techniques and Strategies. 61
31864535 2019
34
Hemolysis-associated hemoglobin cast nephropathy results from a range of clinicopathologic disorders. 61
31668630 2019
35
Plasma levels of soluble membrane attack complex are elevated despite viral suppression in HIV patients with poor immune reconstitution. 61
31461782 2019
36
Paroxysmal nocturnal hemoglobinuria without GPI-anchor deficiency. 61
31638602 2019
37
Hemolytic anemia, spherocytosis, and thrombocytopenia associated with honey bee envenomation in a dog. 61
31228292 2019
38
Case Report: Spherocytic Hemolytic Anemia after Envenomation by Long-Nosed Viper (Vipera ammodytes). 61
31674297 2019
39
Complement and inflammasome overactivation mediates paroxysmal nocturnal hemoglobinuria with autoinflammation. 61
31430258 2019
40
Correction to: prediction of thrombosis risk in patients with paroxysmal nocturnal hemoglobinuria. 61
31729544 2019
41
Fatal acute babesiosis associated with Babesia venatorum infection (Babesia sp. EU1) in a captive reindeer calf in Switzerland. 61
31796172 2019
42
Heme is involved in the systemic inflammatory response following radiofrequency ablation of hepatic hemangiomas. 61
31851092 2019
43
Kerosene, Camphor, and Naphthalene Poisoning in Children. 61
32021004 2019
44
Ethanol embolization of lingual arteriovenous malformations: Positive experience in 52 patients during 11 years. 61
31882310 2019
45
Prevalence of prothrombotic factors in patients with Budd-Chiari syndrome or non-cirrhotic nonmalignant portal vein thrombosis: A hospital-based observational study. 61
31711259 2019
46
Flow Cytometric Diagnosis of Paroxysmal Nocturnal Hemoglobinuria: Pearls and Pitfalls - A Critical Review Article. 61
31814811 2019
47
First exploratory study on the metabolome from plasma exosomes in patients with paroxysmal nocturnal hemoglobinuria. 61
31671376 2019
48
CD71 improves delineation of PNH type III, PNH type II, and normal immature RBCS in patients with paroxysmal nocturnal hemoglobinuria. 61
31705743 2019
49
Effect of anti-C5 antibody on recuperation from ischemia/reperfusion-induced acute kidney injury. 61
31662004 2019
50
Screening for paroxysmal nocturnal hemoglobinuria (PNH) in patients presenting with cerebral sinovenous thrombosis (CSVT): Results of a FLAER based flowcytometry study in Indian patients. 61
31701360 2019

Variations for Hemoglobinuria

Expression for Hemoglobinuria

Search GEO for disease gene expression data for Hemoglobinuria.

Pathways for Hemoglobinuria

Pathways related to Hemoglobinuria according to GeneCards Suite gene sharing:

(show all 12)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.83 PLAUR HP FCGR3B CSF3 CR1 CFI
2
Show member pathways
12.03 THBD F2 CEACAM8 CD58
3
Show member pathways
11.79 CR1 CFI CD59 CD55 C5 C3
4 11.75 CSF3 CEACAM8 CD59
5
Show member pathways
11.74 CR1 CD59 CD55 C5 C3
6 11.7 CSF3 CR1 CD59 CD55
7 11.65 FCGR3B CFI C5 C3
8
Show member pathways
11.65 PLAUR PIGT PIGH PIGA FCGR3B
9 11.6 FCGR3B CR1 C3
10
Show member pathways
11.56 CR1 CFI CD59 CD55 C5 C3
11 11.48 THBD SERPINC1 PLAUR F2 CR1 CFI
12
Show member pathways
11.22 PIGT PIGH PIGA

GO Terms for Hemoglobinuria

Cellular components related to Hemoglobinuria according to GeneCards Suite gene sharing:

(show all 11)
# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 10.06 SERPINC1 PLAUR HP FCGR3B F2 CSF3
2 extracellular space GO:0005615 9.96 THBD SERPINC1 HP F2 CSF3 CFI
3 endoplasmic reticulum lumen GO:0005788 9.8 SERPINC1 PLAUR F2 C3
4 blood microparticle GO:0072562 9.71 SERPINC1 HP F2 C3
5 secretory granule membrane GO:0030667 9.67 FCGR3B CR1 CD58 CD55
6 specific granule membrane GO:0035579 9.65 PLAUR CEACAM8 CD59
7 ficolin-1-rich granule membrane GO:0101003 9.61 CR1 CD58 CD55
8 cell surface GO:0009986 9.56 THBD PLAUR CR1 CEACAM8 CD59 CD58
9 anchored component of membrane GO:0031225 9.55 PLAUR FCGR3B CEACAM8 CD59 CD55
10 extracellular exosome GO:0070062 9.47 SERPINC1 MB HP G6PD FCGR3B F2
11 glycosylphosphatidylinositol-N-acetylglucosaminyltransferase (GPI-GnT) complex GO:0000506 9.46 PIGH PIGA

Biological processes related to Hemoglobinuria according to GeneCards Suite gene sharing:

(show all 14)
# Name GO ID Score Top Affiliating Genes
1 innate immune response GO:0045087 9.92 CR1 CFI CD55 C5 C3
2 leukocyte migration GO:0050900 9.73 THBD F2 CEACAM8 CD58
3 blood coagulation GO:0007596 9.65 THBD SERPINC1 PLAUR F2 CD59
4 neutrophil degranulation GO:0043312 9.61 PLAUR HP FCGR3B CR1 CEACAM8 CD59
5 complement activation, classical pathway GO:0006958 9.55 CR1 CFI CD55 C5 C3
6 preassembly of GPI anchor in ER membrane GO:0016254 9.54 PIGH PIGA
7 hemostasis GO:0007599 9.54 THBD SERPINC1 F2
8 complement activation, alternative pathway GO:0006957 9.51 C5 C3
9 GPI anchor biosynthetic process GO:0006506 9.5 PIGT PIGH PIGA
10 regulation of blood coagulation GO:0030193 9.49 SERPINC1 F2
11 negative regulation of fibrinolysis GO:0051918 9.48 THBD F2
12 negative regulation of platelet activation GO:0010544 9.46 THBD F2
13 regulation of complement-dependent cytotoxicity GO:1903659 9.4 CD59 CD55
14 regulation of complement activation GO:0030449 9.17 F2 CR1 CFI CD59 CD55 C5

Molecular functions related to Hemoglobinuria according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 signaling receptor binding GO:0005102 9.02 PLAUR F2 CD58 C5 C3
2 phosphatidylinositol N-acetylglucosaminyltransferase activity GO:0017176 8.96 PIGH PIGA

Sources for Hemoglobinuria

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....